BCL2 Inhibitor
B-Cell Malignancies (e.g., CLL/SLL)
Late-Stage (Phase 3)Active
Key Facts
Indication
B-Cell Malignancies (e.g., CLL/SLL)
Phase
Late-Stage (Phase 3)
Status
Active
Company
About BeOne Medicines
BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.
View full company profile